Clinical trial · Interventional
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
A Continuation Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
NCT00285675CI-TRIAL-00000346unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Androgen Independent Prostate Cancer (AIPC) | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DN-101 (calcitriol) - Drug | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prior participation in DN101-002 or DN101-004 studies, where the subject received at least one dose of DN-101 * Able and willing to give written informed consent Exclusion Criteria: * Disease progression or unacceptable toxicity while previously enrolled in DN101-002 or DN101-004 studies * Prior investigational therapy other than DN-101 within 30 days of enrollment * Known hypersensitivity to calcitriol * Pregnancy (women of childbearing potential only) * Greater than 90 days has elapsed from termination of DN101-002 or DN101-004 studies
References
Publications (0)
Data not yet available
No reference posted for this study.